Jim Murray is the VP of Clinical Operations at TScan.  He has over 20 years of industry experience and has been involved in the execution of over 40 Phase 1 – Phase 3 clinical studies in oncology, autoimmune and rare disease indications.  He oversaw the global registrational studies that resulted in the FDA approvals of Onivyde and Imcivree.  Prior to TScan, he has been the Head of Clinical Operations at Merrimack Pharmaceuticals, Rhythm Pharmaceuticals and most recently at Repertoire Immune Medicines, where he was the VP of Clinical Operations responsible for the execution of two T-cell therapy programs in oncology.  He received his BS in Biology from Boston College and he completed an executive management program in biotechnology from Harvard Business School.

Away from TScan, he enjoys running, golfing and mountain biking.